{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-23-000833","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.526175+00:00","generated_at":"2026-06-15T02:17:37.178115+00:00","sec_items":["1.0"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Lexaria engages InClin as CRO for Phase 1b hypertension study; budget $1.4M","bullets":["Master Services Agreement with InClin for FDA-registered Phase 1b hypertension study HYPER-H23-1 using DehydraTECH-powered cannabidiol.","Initial work order budget $1,395,000; includes $72,355 (10% direct costs) and $335,242 (50% pass-through costs).","Financing of at least US$1,000,000 completed, making the work order definitive.","Both MSA and work order can be terminated with or without cause on 30 days' notice.","Kick-off meeting between Lexaria and InClin scheduled for late May 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-23-000833","json":"https://secwatch.observer/filing/0001640334-23-000833.json","markdown":"https://secwatch.observer/filing/0001640334-23-000833.md","text":"https://secwatch.observer/filing/0001640334-23-000833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/0001640334-23-000833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033423000833/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:17:37.178115+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}